Peripheral blood progenitor cell transplantation: A replacement for marrow auto- or allografts

Stem Cells

Volumn 14, Issue 2, 1996, Pages 185-195

  Körbling, Martin ^a   Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogenic stem cell transplantation; Apheresis; Autologous stem cell transplantation; Blood stem cells; Breast ovarian cancer; CD34+; Gene therapy; Hematologic malignancies; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; STEM CELL FACTOR;

ALLOTRANSPLANTATION; APHERESIS; AUTOTRANSPLANTATION; BURST FORMING UNIT E; CELL MOTILITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; COLONY FORMING UNIT GM; CRYOPRESERVATION; GENETIC TRANSDUCTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTE;

EID: 0029872721     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140185     Document Type: Review

References (72)

1. Fliedner TM, Steinbach KH. Repopulating potential of hematopoietic precursor cells. Blood Cells 1988;14:393-410.
2. Civin CI, Banquerigo ML, Strauss LC et al. Antigenic analysts of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. Exp Hematol 1987;15:10-17.
3. Craig W, Kay R, Cutler RL et al. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177:1331-1342.
4. Baum CM, Weissman IL, Tsukamoto AS et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992;89:2804-2808.
5. Lu L, Walker D, Broxmeyer HE et al. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My 10 and major histocompatibility class II monoclonal antibodies. J Immunol 1987;139:1823-1829.
6. - progenitor cells. Blood 1991;77:1218-1227.
7. Mayani H, Lansdorp PM. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 1994;83:2410-2417.
8. - subpopulation from mobilized peripheral blood. Blood 1995;85:368-378.
9. dim) and lymphoid subsets, and possible predictors of engraftment and GVHD. Blood 1995;86:2842-2848.
10. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988;241:58-62.
11. - hematopoietic stem cells. Blood 1994.83:3758-3779.
12. Goldman JM. Modern approaches to the management of chronic granulocytic leukemia. Semin Hematol 1978;15:420-430.
13. Körbling M, Burke P, Braine H et al. Successful engraftment of blood-derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 1981;9:684-690.
14. Körbling M, Dorken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529-532.
15. Kessinger A, Armitage JO, Landmark JD et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986;14:192-196.
16. Körbling M, Holle R, Haas R et al. Autologous blood stem-cell transplantation (ABSCT) in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990;8:978-985.
17. Kessinger A, Vose JM, Bierman PJ et al. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. Exp Hematol 1991;19:1013-1016.
18. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete hemopoietic reconstitution after high dose melphalan or supralethal chemotherapy. Br J Haematol 1985;61:739-745.
19. Körbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pAMBT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991;7:343-349.
20. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991;77:211-213.
21. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039.
22. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990;18:442-447.
23. Duhrsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.
24. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-644.
25. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-1719.
26. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992;79:1193-1200.
27. Engel H, Körbling M, Palmer J et al. Randomized trial of G-CSF alone vs sequential interleukin-3 (IL-3) and G-CSF treatment to peripheralize progenitor cells for apheresis and blood stem cell autotransplantation in patients with advanced stage breast cancer. Blood 1994;84(suppl 1):108a.
28. Andrews RG, Briddell RA, Knitter GH et al. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995;85:15-20.
29. Tong J, Gordon MS, Srour E et al. In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood 1993;82:784-791.
30. Matsunaga T, Sakamaki S, Kohgo Y et al. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993;11:103-108.
31. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995,85:1659-1665.
32. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658.
33. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte-stimulating factor Blood 1994;84:2795-2801.
34. Pettengell R, Luft T, Henschler R et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994;84:3653-3659.
35. Molineux G, Pojda Z, Hampson IN et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990;76:2153-2158.
36. Dale DC, Bolyard AA, Hammond WP. Cyclic neutropenia: natural history and effects of long-term treatment with recombinant human granulocyte colony-stimulating factor. Cancer Invest 1993;11:219-223.
37. Malachowski ME, Comenzo RL, Hillyer CD et al. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992;32:732-735.
38. Comenzo RI, Malachowski ME, Miller KB et al. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 1992;32:729-731.
39. Passos-Coelho JL, Braine HG, Wright SK et al. Large volume leukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J Hematother 1995;4:11-19.
40. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Perez-Romano B et al. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy Am J Hematol 1995;48:100-103.
41. Eckhardt JR, Roodman GD, Boldt DH et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant 1993;11:125-131.
42. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
43. Körbling M, Juttner C, Hénon P et al. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant 1992;10(suppl 1):144-148.
44. To LB, Roberts MM, Hay lock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-284.
45. Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;82:2324-2328.
46. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-2035.
47. Janssen WE, Perkins J, Hiemenz JW et al. Granulocyte recovery is not different following auto-transplant with G-CSF primed bone marrow or G-CSF mobilized peripheral blood "stem cells." Blood 1994;84(suppl 1):95a.
48. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048-3057.
49. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-1672.
50. Carella AM, Podesta M, Frassoni F et al. Collection of 'normal' blood repopulating cells during early hematopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993;12:267-271.
51. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-640.
52. Moss TJ, Sanders DG, Lasky LC et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990;76:1879-1883
53. Sharp JG, Kessinger A, Vaughan WP et al. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Cloning 1992;10(suppl 1):92-97.
54. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-2610.
55. Moss TJ. The clinical significance of occult tumor cells in stem cell harvests: is purging necessary. Proceedings of the IBC's 2nd International Conference on Hematopoietic Stem Cells. April 24-25, 1995, San Diego, CA.
56. Negrin RS, Kusnierz-Glaz CR, Still BJ et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma (NHL). Blood 1994;84(suppl 1):396a.
57. Przepiorka D, Van Vlasselaer P, Huynh L et al. Ultralight percoll gradient separation of filgrastim-mobilized peripheral blood mononuclear cells from normal donors: comparison of manual vs automated techniques. J Hematother 1995;4:193a.
58. Van Den Berg D, Carella A, Negrin R et al. Potential use of normal stem cells isolated from mobilized peripheral blood of CML patients as an autograft. Blood 1994;84(suppl 1):400a.
59. - stem cells from mobilized peripheral blood by high speed fluorescence-activated cell sorting for use as an autograft for multiple myeloma patients. Blood 1994;84(suppl 1):399a.
60. - hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant 1994;13:649-654.
61. Brenner MK, Rill DR. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother 1994;3:33-36.
62. Rill DR, Buschle M, Foreman NK et al Retrovirus mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther 1992;3:129-136.
63. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-3076.
64. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion (in press).
65. Goldman J. Peripheral blood stem cells for allografting (Editorial). Blood 1995;85:1413-1415.
66. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem cell transplantation: reduction in early treatment-related morbidity and mortality for patients with advanced hematologic malignancies. Bone Marrow Transplant (in press).
67. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity, laboratory effects and cost analysis of filgrastim mobilization and blood stem cell apheresis from normal donors. Transfusion (in press).
68. Tepler I, Cannistra SA, Frei E III et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993;11:1583-1591.
69. Körbling M, Przepiorka D, Gajewski J et al. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? (Correspondence) Blood 1995;86:1235.
70. Sorrentino BP, Brandt SJ, Bodine D et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDRI. Science 1992;257:99-103.
71. Hanania EG, Fu S, Zu Z et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Therapy 1995;2:285-294.
72. Hanania EG, Fu S, Roninson I et al. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Therapy 1995;2:279-284.